Moderna (NASDAQ:MRNA) Stock Rating Lowered by Barclays

Barclays lowered shares of Moderna (NASDAQ:MRNA) from an overweight rating to an equal weight rating in a report published on Tuesday morning, Marketbeat Ratings reports. Barclays currently has $45.00 target price on the stock, down from their previous target price of $111.00.

A number of other analysts have also commented on the stock. Piper Sandler reaffirmed an “overweight” rating and set a $69.00 target price (down previously from $115.00) on shares of Moderna in a report on Monday, November 18th. The Goldman Sachs Group lowered shares of Moderna from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $99.00 to $51.00 in a report on Wednesday, January 29th. JPMorgan Chase & Co. lowered their target price on shares of Moderna from $59.00 to $45.00 and set an “underweight” rating for the company in a report on Tuesday, November 26th. Morgan Stanley reduced their price target on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a research report on Wednesday, January 15th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research report on Friday, November 8th. Four analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $60.63.

Moderna Trading Down 6.0 %

NASDAQ MRNA opened at $33.73 on Tuesday. The firm has a market cap of $12.98 billion, a price-to-earnings ratio of -3.63 and a beta of 1.59. The company has a 50 day moving average of $38.17 and a 200-day moving average of $53.20. Moderna has a 1-year low of $29.25 and a 1-year high of $170.47.

Insider Buying and Selling at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the sale, the insider now owns 19,717 shares of the company’s stock, valued at $843,690.43. The trade was a 6.71 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders sold 2,664 shares of company stock valued at $115,210 in the last quarter. Company insiders own 15.70% of the company’s stock.

Institutional Trading of Moderna

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Forum Financial Management LP bought a new stake in shares of Moderna during the 4th quarter worth approximately $225,000. Blue Sky Capital Consultants Group Inc. bought a new position in Moderna in the 4th quarter valued at approximately $606,000. GF Fund Management CO. LTD. bought a new position in Moderna in the 4th quarter valued at approximately $372,000. Vega Investment Solutions bought a new position in Moderna in the 4th quarter valued at approximately $45,000. Finally, Alpine Global Management LLC bought a new position in Moderna in the 4th quarter valued at approximately $224,000. Institutional investors own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.